RESUMO
The present study evaluated the outcome of Dacryocystorhinostomy with silicone intracystic implant in patients with chronic dacryocystitis, in terms of Operative time involved, Success rate achieved (patency of the tract) and Complications on an out patient basis in the Postgraduate department of Ophthalmology, Government Medical College, Hospital, Jammu during the year 2010-2011. A group of 40 patients with obstruction of nasolacrimal duct were treated with DCR with silicone intracystic implant. Maximum no. of patients(65%) were <65yrs of age, the youngest patient being 20yrs old with a Female:Male ratio of 2.3:1. The disease was more common on the left side with Left: Right ratio of 1.6:1. The success rate of the procedure was 90% which was statistically and clinically significant.
RESUMO
The study was conducted on 50 patients attending the Eye OPDs of Ophthalmology Department of Government Medical College Jammu during the year. 25 patients were clinically diagnosed to have Retinal Vein Occlusion and were compared with 25 age and sex matched controls. The axial lengths of both eyes of all 50 patients were measured using A-Scan Biometry, the data was analyzed by student t-test and chisquare test.It was concluded that the axial lengths in retinal vein occlusion were significantly shorter than the controls. This significant difference can be a risk factor in the development of retinal vein occlusion.
RESUMO
In this prospective randomized parallel study we compared the effects of topical timolol maleate, levobunolol hydrochloride and betaxolol hydrochloride on intraocular pressure (IOP) in the patients of primary open angle glaucoma after 16 weeks of instillation as 1 drop 12 hourly in 0.5% concentration. 23 eyes of 16, 19 eyes of 12 and 20 eyes of 12 patients were included in timolol, levobunolol and betaxolol groups respectively. Timolol, levobunolol and betaxolol lowered IOP by 13.05 ± 1.53, 14.05 ±1.47 and 7.58 ± 0.90mmof Hg respectively after 6weeks and by16.12±1.67,16.28 ±1.85 and 8.535 ± 0.983 mm of Hg respectively after 16 weeks (P<0.001). Both levobunolol and timolol produced greater reduction in IOP than betaxolol (P<0.001). The results of our study indicated that betaxolol is less efficacious in lowering IOP in Indian patients and could only be preferred over timolol in glaucoma patients with associated chronic obstructed pulmonary disease (COPD) or bronchial asthma. However, Levobunolol could be a better alternative to timolol , as being a longer acting agent with IOP control for 24 hrs after single instillation and can be used as once a day instillation with better safety profile.